Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697519 | 0.81 | TLR2 (0.33) | NMT2NMT1 | |
| SCHEMBL31538110 | 0.80 | CA2 (0.35) | GLP1RMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25701620 | 0.79 | CA2 (0.34) | SMN1; SMN2 | |
| SCHEMBL31697409 | 0.77 | EPHX2 (0.36) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25696350 | 0.77 | EPHX2 (0.36) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25046488 | 0.76 | CCKAR (0.38) | CHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL22618814 | 0.74 | FFAR1 (0.32) | ITGB1ITGA4 | |
| SCHEMBL31575300 | 0.74 | NMT2 (0.36) | NMT2NMT1ITGB1ITGA4 | |
| SCHEMBL23193205 | 0.73 | GLP1R (0.32) | GLP1R | |
| SCHEMBL31217941 | 0.73 | TLR2 (0.36) | PIK3CDPIK3CAPIK3CGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | KEYMED BIOSCIENCES (CHENGDU) CO., LTD. (CN) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | GLP1R 2431/4885NMT2 227/4885NMT1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.